SE0003449L - Cancerhämmande kompositioner - Google Patents

Cancerhämmande kompositioner

Info

Publication number
SE0003449L
SE0003449L SE0003449A SE0003449A SE0003449L SE 0003449 L SE0003449 L SE 0003449L SE 0003449 A SE0003449 A SE 0003449A SE 0003449 A SE0003449 A SE 0003449A SE 0003449 L SE0003449 L SE 0003449L
Authority
SE
Sweden
Prior art keywords
cancer
inhibiting compositions
paclitaxel
formulated
dosage forms
Prior art date
Application number
SE0003449A
Other languages
English (en)
Swedish (sv)
Other versions
SE0003449D0 (sv
Inventor
Indu Parikh
Iskandar Moussa
Alain Carrier
Original Assignee
Rtp Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rtp Pharma Inc filed Critical Rtp Pharma Inc
Publication of SE0003449D0 publication Critical patent/SE0003449D0/xx
Publication of SE0003449L publication Critical patent/SE0003449L/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SE0003449A 1998-04-01 2000-09-27 Cancerhämmande kompositioner SE0003449L (sv)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8027398P 1998-04-01 1998-04-01
US8027298P 1998-04-01 1998-04-01
PCT/US1999/007162 WO1999049848A1 (en) 1998-04-01 1999-03-30 Anticancer compositions

Publications (2)

Publication Number Publication Date
SE0003449D0 SE0003449D0 (sv) 2000-09-27
SE0003449L true SE0003449L (sv) 2000-11-23

Family

ID=26763305

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0003449A SE0003449L (sv) 1998-04-01 2000-09-27 Cancerhämmande kompositioner

Country Status (12)

Country Link
EP (1) EP1067908B9 (https=)
JP (1) JP4695260B2 (https=)
KR (1) KR100661879B1 (https=)
CN (1) CN100341485C (https=)
AT (1) ATE327735T1 (https=)
AU (1) AU756752B2 (https=)
CA (1) CA2326485C (https=)
DE (1) DE69931617T2 (https=)
IL (2) IL138767A0 (https=)
SE (1) SE0003449L (https=)
TW (1) TW546152B (https=)
WO (1) WO1999049848A1 (https=)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6964946B1 (en) * 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
US7255877B2 (en) 1996-08-22 2007-08-14 Jagotec Ag Fenofibrate microparticles
KR100615783B1 (ko) * 1997-05-27 2006-08-25 아이박스 리서치 인코포레이티드 탁산 치료를 받고 있는 인체를 제외한 포유동물의 과민증 또는 알러지 반응을 경감시키기 위한 방법 및 약학적 키트
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
EP1479382A1 (en) * 1999-06-18 2004-11-24 IVAX Research, Inc. Oral pharmaceutical compositions containing taxanes and methods for treatment employing the same
AU2006201100B2 (en) * 1999-09-21 2009-09-24 Jagotec Ag Surface modified particulate compositions of biologically active substances
ATE296091T1 (de) * 1999-09-21 2005-06-15 Skyepharma Canada Inc Oberflächenmodifizierte teilchenförmige zusammensetzungen biologisch aktiver stoffe
AU7638300A (en) * 1999-10-20 2001-04-30 Vesifact Ag Microemulsion preconcentrates and microemulsions
IL149360A0 (en) * 1999-10-27 2002-11-10 Baker Norton Pharma Method and compositions for administering taxanes orally to human patients
EP1118333A1 (en) * 2000-01-18 2001-07-25 Eurand International S.P.A. Compositions with enhanced oral bioavailability
DE10030378A1 (de) * 2000-06-21 2002-03-14 Audit Inst For Medical Service Neue pharmazeutische Zusammensetzung zur topischen Anwendung von wasserunlöslichen und/oder schwer wasserlöslichen Wirkstoffen
ATE290372T1 (de) * 2000-07-24 2005-03-15 Upjohn Co Selbstemulgierendes system zur abgabe von sehr wasserunlöslichen und lipophilen arzneimitteln
JP2004536026A (ja) 2000-11-28 2004-12-02 トランスフォーム ファーマシューティカルズ，インコーポレーティッド． パクリタキセル、その誘導体、および薬剤として許容される塩を含む医薬品製剤
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US6884436B2 (en) 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US7193084B2 (en) 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US6869617B2 (en) 2000-12-22 2005-03-22 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US6977085B2 (en) 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US6951656B2 (en) 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
PT1249231E (pt) * 2001-04-12 2004-06-30 Vesifact Ag Formulacoes farmaceuticas contendo substancias activas anti-inflamatorias e sua utilizacao
KR100774366B1 (ko) * 2001-09-10 2007-11-08 주식회사 중외제약 파클리탁셀 주사제 조성물
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
US7112340B2 (en) 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
US20040092428A1 (en) * 2001-11-27 2004-05-13 Hongming Chen Oral pharmaceuticals formulation comprising paclitaxel, derivatives and methods of administration thereof
EP1460992B1 (en) * 2001-12-03 2009-03-11 Dor Biopharma, Inc. Stabilized reverse micelle compositions and uses thereof
JP4526120B2 (ja) * 2002-05-22 2010-08-18 日本製薬株式会社 Ｌ−メントール水中油型乳剤
KR20040008816A (ko) * 2002-07-19 2004-01-31 한미약품 주식회사 파클리탁셀 또는 그의 유도체와 ｐ-당단백질 저해제를함유하는 혈관재협착 방지를 위한 경구투여용 약학 조성물
KR100573289B1 (ko) * 2002-07-20 2006-04-24 대화제약 주식회사 방광내 투여를 통한 방광암치료용 파클리탁셀 조성물 및그의 제조 방법
DE10247399A1 (de) * 2002-10-08 2004-04-29 Schering Ag Pharmazeutische Zubereitungen, Verwendung dieser Zubereitung und Verfahren zur Erhöhung der Bioverfügbarkeit von peroral zu applizierenden Arzneistoffen
EP1498143A1 (en) * 2003-07-18 2005-01-19 Aventis Pharma S.A. Self-emulsifying and self-microemulsifying formulations for the oral administration of taxoids
EP1498120A1 (en) * 2003-07-18 2005-01-19 Aventis Pharma S.A. Semi-solid formulations for the oral administration of taxoids
WO2005037251A1 (en) * 2003-10-17 2005-04-28 Amylin Pharmaceuticals, Inc. Self-emulsifying drug delivery systems for hydrophobic therapeutic compounds
WO2005037250A1 (en) * 2003-10-17 2005-04-28 Amylin Pharmaceuticals, Inc. Self emulsifying drug delivery systems for hydrophobic therapeutic compounds
NZ549016A (en) 2004-02-13 2012-03-30 Bioavailability Inc A microemulsion preparation of high concentration propofol for anesthetic uses
CA2560298A1 (en) * 2004-03-24 2005-09-29 Takeda Pharmaceutical Company Limited Preparation with elevated content
US7345093B2 (en) 2004-04-27 2008-03-18 Formatech, Inc. Methods of enhancing solubility of compounds
US7659310B2 (en) 2004-04-27 2010-02-09 Formatech, Inc. Methods of enhancing solubility of agents
FR2873585B1 (fr) * 2004-07-27 2006-11-17 Aventis Pharma Sa Nouvelles formulations galeniques de principes actifs
CN100361656C (zh) 2004-08-27 2008-01-16 石药集团中奇制药技术（石家庄）有限公司 丁苯酞自乳化释药体系及其制备方法和应用
MX2007011250A (es) * 2005-03-21 2007-11-14 Ivax Pharmaceuticals Sro Inhibidor de la cristalizacion y su uso en capsulas de gelatina.
WO2008058366A1 (en) * 2006-09-28 2008-05-22 Université de Montréal Oil-in-water emulsions, methods of use thereof, methods of preparation thereof and kits thereof
US20090088393A1 (en) * 2007-09-28 2009-04-02 Zomanex, Llc Methods and formulations for converting intravenous and injectable drugs into oral dosage forms
EP2204167A1 (en) 2009-01-05 2010-07-07 Azad Pharma AG Pharmaceutical microemulsion for preventing supramolecular aggregation of amphiphilic molecules
CN101785757B (zh) * 2009-01-22 2012-02-22 美迪思生物科技(北京)有限公司 一种紫杉醇自乳化制剂及其制备方法和用途
EP2301523A1 (de) 2009-09-22 2011-03-30 Dr. August Wolff GmbH & Co. KG Arzneimittel Galenische Formulierung in kolloidaler Form
CA2781529C (en) 2009-09-23 2017-10-24 Indu Javeri Methods for the preparation of liposomes comprising docetaxel
US10143652B2 (en) 2009-09-23 2018-12-04 Curirx Inc. Methods for the preparation of liposomes
CN102228431A (zh) * 2010-03-16 2011-11-02 王国强 紫杉烷类化合物的自乳化药物组合物
EA027666B1 (ru) * 2010-05-03 2017-08-31 ТЕИКОКУ ФАРМА ЮСЭй, ИНК. Неводные лекарственные средства в форме проэмульсии на основе таксанов и способы их приготовления и использования
US20120095098A1 (en) * 2010-10-18 2012-04-19 Bhiku Patel Bioavailability Enhancement Delivery System
JO3685B1 (ar) * 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
EP2878311A1 (en) * 2013-11-27 2015-06-03 Freund Pharmatec Ltd. Solubility Enhancement for Hydrophobic Drugs
EP3086777A1 (en) * 2013-12-23 2016-11-02 Johnson & Johnson Consumer Inc. Racecadotril compositions
DE102014015625A1 (de) 2014-10-16 2016-04-21 Gonzalo Urrutia Desmaison Lösungsvermittelnde Zusammenssetzungen
KR101542364B1 (ko) * 2014-10-31 2015-08-07 대화제약 주식회사 탁산을 포함하는 경구 투여용 약학 조성물
EP3326652B1 (en) * 2015-07-30 2021-10-06 Dae Hwa Pharma. Co., Ltd Pharmaceutical composition for oral administration comprising high concentration taxane
TWI838700B (zh) * 2015-09-30 2024-04-11 香港商慧源香港創新有限公司 口服紫杉烷組合物及方法
CN109589305B (zh) * 2018-12-03 2021-03-19 昆明积大制药股份有限公司 多西他赛-环孢素a共包载自乳化制剂及其制备方法
US20220096376A1 (en) * 2019-01-07 2022-03-31 Pusan National University Industry-University Cooperation Foundation Drug delivery platform using w/o/w-type triolein emulsion promotive of blood-brain barrier opening
PL241264B1 (pl) * 2020-02-19 2022-08-29 Inventionbio Spółka Akcyjna Samoemulsyfikująca kompozycja, przeznaczona do podawania naskórnego, zawierająca biosurfaktant, ko-surfaktant oraz fazę olejową

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU680441B2 (en) * 1992-09-22 1997-07-31 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Use of taxol for treating lymphomas and breast cancer
US5567592A (en) * 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
US5616330A (en) * 1994-07-19 1997-04-01 Hemagen/Pfc Stable oil-in-water emulsions incorporating a taxine (taxol) and method of making same
US5560931A (en) * 1995-02-14 1996-10-01 Nawosystems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
GB9509321D0 (en) * 1995-05-09 1995-06-28 Zylepsis Ltd Methods of and substances for inhibiting oxidative enzymes
TW527186B (en) * 1996-03-19 2003-04-11 Janssen Pharmaceutica Nv Fused imidazole derivatives as multidrug resistance modulators
US5919815A (en) * 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
US6060518A (en) * 1996-08-16 2000-05-09 Supratek Pharma Inc. Polymer compositions for chemotherapy and methods of treatment using the same
PL335891A1 (en) * 1997-03-27 2000-05-22 Baker Norton Pharma Methods of and compositions for treating ovarian carcinoma

Also Published As

Publication number Publication date
EP1067908B9 (en) 2007-01-24
WO1999049848A1 (en) 1999-10-07
ATE327735T1 (de) 2006-06-15
JP4695260B2 (ja) 2011-06-08
DE69931617D1 (de) 2006-07-06
EP1067908A1 (en) 2001-01-17
AU756752B2 (en) 2003-01-23
JP2002509877A (ja) 2002-04-02
KR20010034622A (ko) 2001-04-25
SE0003449D0 (sv) 2000-09-27
CN100341485C (zh) 2007-10-10
DE69931617T2 (de) 2007-05-24
IL138767A0 (en) 2001-10-31
AU3377099A (en) 1999-10-18
KR100661879B1 (ko) 2006-12-27
CN1303269A (zh) 2001-07-11
CA2326485C (en) 2008-12-09
EP1067908B1 (en) 2006-05-31
IL138767A (en) 2007-06-03
CA2326485A1 (en) 1999-10-07
TW546152B (en) 2003-08-11

Similar Documents

Publication Publication Date Title
SE0003449L (sv) Cancerhämmande kompositioner
ATE356612T1 (de) Orale, pharmazeutische darreichungsformen von flüssigen medikamenten mitverbesserter bioverfügbarkeit
ATE293995T1 (de) Pharmazeutische zusammensetzungen, die wirkstoffabsorptionsfördernde verbindungen enthalten
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
EE200200357A (et) Ravimaine suurenenud kontsentratsioone andvad farmatseutilised kompositsioonid
ATE224717T1 (de) Oral anzuwendende arzneizubereitungen enthaltend eine benzhydrylpiperazine und eine zyklodextrin
ATE509616T1 (de) Topische pharmazeutische und/oder cosmetische dosierungssysteme
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
NO953278D0 (no) Fremgangsmåter for in vivo-levering av biologisk aktive stoffer og sammensetninger som er nyttige for dette
WO2006035417A3 (en) Dihydropyrimidine microcapsule - formulations
ATE202931T1 (de) Taxanderivate enthaltende arzneizubereitungen
ATE270544T1 (de) Halbfeste arzneizubereitung enthaltend isotretinoin
EP1391200A4 (en) DRUG
ATE292453T1 (de) Antivirale arznei
CY1107295T1 (el) Σταθεροποιηση στερεων φορμουλων φαρμακων του θυρεοειδους
DE60202590D1 (de) 2h-1-benzopyran-derivate, prozesse zu ihrer herstellung und pharmazeutische zusammensetzungen
DE60003188D1 (de) Paracetamol und drotaverin enthaltende zusammensetzung
ATE347886T1 (de) Arzneizubereitungen enthaltend paclitaxel eingeschlossen in nanopartikeln von polymerischen mizellen
TR200601092T1 (tr) İrbesartan etkin maddesi içeren yeni oral farmasötik formülasyonlar.
ATE256134T1 (de) Sulfatierte phosphatidylinositole, ihre herstellung und verwendung
PT1233786E (pt) Produto contendo pelo menos uma substancia inibidora das no sintases associada a pelo menos uma substancia inibidora das fosfolipases a2 para preparacao de um medicamento
DE50005282D1 (de) Medikament sowie aufeinander abgestimmte kombination von medikamenten
ATE227984T1 (de) Mittel gegen malaria und babesia und diese enthaltende pfarmazeutische zubereitungen
ATE335491T1 (de) Arzneimittel gegen glomerulosclerose
EA200101157A1 (ru) 14β-H-СТЕРОЛЫ, СОДЕРЖАЩИЕ ИХ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ И ПРИМЕНЕНИЕ ЭТИХ ПРОИЗВОДНЫХ ДЛЯ ПРИГОТОВЛЕНИЯ ЛЕКАРСТВЕННЫХ СРЕДСТВ, РЕГУЛИРУЮЩИХ МЕЙОЗ

Legal Events

Date Code Title Description
NAV Patent application has lapsed